Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Odronextamab
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Doxorubicin
Drug: Prednisone/Prenisolone
Drug: Vincristine

First Posted Date: 2023-10-24

Last Posted Date: 2025-04-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 733

Registration Number: NCT06097364

Locations: 🇮🇱
The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇱
Assuta Medical Centers, Tel Aviv, Israel
🇮🇹
University of Pisa, Section of Hematology, Pisa, Italy

and more 104 locations

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Drug: Rituximab
Drug: Odronextamab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone/Prednisolone

First Posted Date: 2023-10-19

Last Posted Date: 2025-05-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 904

Registration Number: NCT06091865

Locations: 🇰🇷
Seoul St Marys Hospital, Seoul, Korea, Republic of
🇲🇾
Hospital Ampang, Ampang, Pahang, Malaysia
🇪🇸
Hospital General Universitario de Toledo, Toledo, Spain

and more 146 locations

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Drug: Odronextamab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone/prednisolone
Drug: Bendamustine

First Posted Date: 2023-10-19

Last Posted Date: 2025-05-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 478

Registration Number: NCT06091254

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
HOPE Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 168 locations

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Completed

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)

Interventions: Other: Non-Interventional

First Posted Date: 2023-10-03

Last Posted Date: 2023-10-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 131

Registration Number: NCT06064656

Locations: 🇺🇸
Regeneron, Tarrytown, New York, United States

Compassionate Use of Vidutolimod

First Posted Date: 2023-10-03

Last Posted Date: 2025-03-25

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT06063746

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Conditions: Paroxysmal Nocturnal Hemoglobinuria

First Posted Date: 2023-09-08

Last Posted Date: 2023-09-08

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT06028594

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Phase 1

Active, not recruiting

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Steatohepatitis (NASH)
Genetic Risk Factor

Interventions: Drug: Placebo
Drug: ALN-PNP

First Posted Date: 2023-09-06

Last Posted Date: 2025-02-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT06024408

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheong Buk-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 2 locations

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

Withdrawn

Conditions: Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes
Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF)
Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene